# Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis

> **NCT04523402** · PHASE2 · UNKNOWN · sponsor: **Eastern Hepatobiliary Surgery Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma Recurrent

## Interventions

- **DRUG:** Neoadjuvant chemotherapy

## Key facts

- **NCT ID:** NCT04523402
- **Lead sponsor:** Eastern Hepatobiliary Surgery Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-31
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04523402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04523402, "Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04523402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*